4Weill H, Hughes JM, Churg AM. Changing trends in US mesothclioma incidence [ J]. Occup Environ Med, 2004,61 : 438- 441.
5Manegold C. Coordinating author for the ESMO Guidelines Working Group. Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment, and follow-up [ J ]. Ann Oncol,2007,18 : ii34-ii35.
6Flores RM, Krug LM,Rosenzweig KE, et al, Induction chemotherapy, extrapleural pneumonectomy, and postoperative highdose radiotherapy for locally advanced malignant pleural mesothelioma:A phase II trial[ J]. J Thorac Oncol,2006,1:289- 295.
7Hazarika M,White RM,Johnson JR,et al. FDA drug approval summaries: pemetrexed (alimta) [ J ]. Oncologist, 2004,9 : 482- 488.
8Zhao R,Babani S,Gao F,et al. The mechanism of transport of the multitargeted antifolate MTA-LY231514, and its cross-resistance pattern in cell with impaired transport of methotrexed [ J]. Clin Cancer Res,2000,6:3687-3695.
9Miles DW, Smith IE, Coleman RE, et al. A phase II study of pemetrexed disodium( LY231514 )in patients with locally recurrent or metastatic breast cancer[ J]. Eur J Cancer,2001,37 : 1366-1371.
10Spielmann M, Martin M, Namer M, et al. Activity of pemetrcxed( ALIMTA, multitargeted antifolate, LY231514 ) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis [ J ]. Clin Breast Cancer,2001,2:47-51.
9Grcnberg B H, Bremnes R M. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first- line chemotherapy in advanced non-small-cell lung cancer [J]. J CIin Oncol, 2009,27 (19) : 3217-3224.
10Klein R. Cost-effectiveness of pemetrexed plus cisplatin as first- line therapy for advanced nonsquamous non-small cell lung cancer [J]. J Thorac Oncol, 2009,4( 11 ) : 1404-1414.
